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Objectives The purpose of this study was to investigate the 5-year outcome following transcatheter aortic valve implanta-
tion (TAVI).
Background Little is known about long-term outcomes following TAVI.
Methods The 5-year outcomes following successful TAVI with a balloon-expandable valve were evaluated in 88 patients.
Patients who died within 30 days after TAVI were excluded.
Results Mean aortic valve gradient decreased from 46  18 mm Hg to 10  4.5 mm Hg after TAVI and 11.8  5.7 mm Hg
at 5 years (p for post-TAVI trend  0.06). Mean aortic valve area increased from 0.62  0.17 cm2 to 1.67 
0.41 cm2 after TAVI and 1.40  0.25 cm2 at 5 years (p for post-TAVI trend 0.01). At 5 years, 3 patients (3.4%)
had moderate prosthetic valve dysfunction (moderate transvalvular regurgitation in 1, moderate stenosis in 1,
and moderate mixed disease in 1). Survival rates at 1 to 5 years were 83%, 74%, 53%, 42%, and 35%, respec-
tively. Median survival time after TAVI was 3.4 years (95% confidence interval [CI]: 2.6 to 4.3), and the risk of
death was significantly increased in patients with chronic obstructive pulmonary disease (adjusted hazard ratio
[HR]: 2.17; 95% CI: 1.28 to 3.70) and at least moderate paravalvular regurgitation (adjusted HR: 2.98; 95% CI:
1.44 to 6.17).
Conclusions Our study demonstrated favorable long-term outcomes after TAVI. Signs of moderate prosthetic valve failure were
observed in 3.4% of patients. No patients developed severe prosthetic regurgitation or stenosis. Comorbidities, nota-
bly chronic lung disease and at least moderate paravalvular regurgitation, were associated with reduced long-term
survival. (J Am Coll Cardiol 2013;61:413–9) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.010(
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gPrevious reports of transcatheter aortic valve implantation
(TAVI) have focused on short- and mid-term outcomes
(1–5). A few studies have reported outcomes up to 2 or 3
ears (6–9); however, long-term in vivo durability of trans-
atheter heart valves (THVs) and long-term clinical out-
omes are unknown. The aim of this study was to evaluate
linical and hemodynamic outcomes 5 years after TAVI.
ethods
tudy population. Between January 2005 and March
007, 111 patients underwent TAVI for the treatment of
evere symptomatic aortic stenosis at St Paul’s Hospital
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Manuscript received August 19, 2012; revised manuscript received November 1,
d2012, accepted November 6, 2012.Vancouver, British Columbia, Canada) with the balloon-
xpandable Cribier-Edwards or Edwards SAPIEN valve
Edwards Lifesciences, Irvine, California). All patients pro-
ided written informed consent for the procedure. After
AVI, patients were treated with aspirin (lifelong) and
lopidogrel (for 3 months). If oral anticoagulation was
ndicated, patients were treated with warfarin and dual
ntiplatelet therapy (for 3 months) if tolerated.
These initial 111 patients represent the first in-human
xperience with transarterial and transapical TAVI in truly
noperable patients, and many steps of the procedure were
ot standardized at that time. Therefore, peri-procedural
ortality was relatively high. Because the focus of this paper
as to evaluate 5-year outcome following TAVI, patients
ith unsuccessful valve implantation and patients who died
ithin 30 days were excluded from analysis, leaving a total
f 88 patients who were analyzed (Fig. 1).
ata collection and definitions. Clinical and echocardio-
raphic data were prospectively entered into a dedicated
atabase at baseline, at hospital discharge, at 30 days, and
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diography was performed before
TAVI, at a median of 3 days
after TAVI (but before dis-
charge), and yearly thereafter ac-
cording to the guidelines (10).
Left ventricular ejection fraction
was calculated using the biplane
Simpson method. Severity of re-
gurgitation was graded as none/
trivial, mild, moderate, or severe,
integrating structural, Doppler,
and quantitative parameters ac-
cording to guidelines (11). Pul-
monary hypertension was de-
fined as pulmonary artery systolic pressure 60 mm Hg as
estimated by Doppler echocardiography or measured by
cardiac catheterization (6). Clinical endpoints and pros-
hetic valve dysfunction were defined according to the Valve
cademic Research Consortium (12,13). Five-year
ollow-up was available for 84 of 88 patients (96%).
tatistical analysis. Continuous variables are described
sing mean SD or medians with first (Q1) and third (Q3)
quartiles in cases of skewed distributions. Categorical vari-
ables are described by frequencies and percentages. Differ-
ences between independent groups were tested using the
Wilcoxon rank-sum test and Student t test for continuous
ariables. In cases in which the samples were paired, the
ilcoxon signed rank or paired Student t test were used.
Categorical variables were compared with the chi-square
test. Survival rates at 1 to 5 years were estimated and
graphed using the Kaplan-Meier method. A Cox regression
model was used to estimate hazard ratios (HRs) and 95%
CIs of baseline and procedural characteristics on outcome.
Variables were included in the multivariable model if they
were univariately significant at 0.25. Linear mixed-effects
models were fit to assess any change in either the aortic valve
area or mean gradient from post-TAVI to 5-year follow-up.
Individual growth curves were fit with random effects for
Figure 1 Study Patients
Patients with unsuccessful valve implantation and patients who died
within 30 days were excluded from analysis.
Abbreviations
and Acronyms
COPD  chronic
obstructive pulmonary
disease
MR  mitral regurgitation
PAR  paravalvular
regurgitation
SAVR  surgical aortic
valve replacement
TAVI  transcatheter aortic
valve implantation
THV  transcatheter heart
valveiboth intercept and yearly rate of change and assuming an
unstructured covariance structure. Analyses were conducted
with SAS version 9.2 (SAS Institute, Inc., Cary, North
Carolina) and tested using 2-sided tests at a significance
level of 0.05.
Results
Procedural outcome and survival. A total of 88 patients
with a mean age of 83  7 years were analyzed. Baseline
characteristics are summarized in Table 1. Valves implanted
were the Cribier-Edwards in 49 (56%) and the SAPIEN
Baseline Characteristics (N  88)Table 1 Baseline Characteristics (N  88)
Age, yrs 83 7
Female 41 (47)
Diabetes 22 (25)
Hypertension 61 (69)
Coronary artery disease 63 (72)
Previous myocardial infarction 69 (78)
Previous open heart surgery 34 (39)
Previous cerebrovascular accident 14 (16)
COPD 23 (26)
GFR 60 ml/min 47 (53)
Pulmonary hypertension 17 (19)
Atrial fibrillation 45 (51)
STS PROM score, % 9.0 (6.1, 12.8)
Mean gradient, mm Hg 46 18
Aortic valve area, cm2 0.62 0.17
Ejection fraction, % 60 (50, 65)
Values are mean  SD, n (%), or median (Q1, Q3).
COPD  chronic obstructive pulmonary disease; GFR  glomerular filtration rate; STS
PROM  Society of Thoracic Surgeons Predicted Risk of Mortality.
Procedural Characteristicsand 30-D y Outcome (N  88)Table 2 Pro edu al Characteristicsand 30-Day Outcome (N  88)
Valve type* 49 (56)
Cribier-Edwards 39 (44)
Edwards SAPIEN
Valve size 31 (35)
23 mm 57 (65)
26 mm
Access 64 (73)
Transfemoral 24 (27)
Transapical
Mean gradient post-TAVI, mm Hg 10.0 4.5
Aortic valve area post-TAVI, cm2 1.67 0.41
At least moderate PAR 9 (10)
Major vascular complication 9 (10)
Major or life-threatening bleeding 13 (15)
Major stroke 1 (1)
Permanent pacemaker implant 6 (7)
Coronary occlusion 0 (0)
New hemodialysis 1 (1)
Mortality* 0 (0)
Values are n (%) or mean  SD. *Patients with unsuccessful TAVI in which no valve was
mplanted and patients who died within 30 days were excluded from analysis.
PAR  paravalvular regurgitation; TAVI  transcatheter aortic valve implantation.
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January 29, 2013:413–9 5-Year Outcome After TAVI(Edwards Lifesciences) in 39 (44%). Access was transfemo-
ral (64 patients [73%]) and later also transapical (24 patients
[27%]). Procedural characteristics and outcomes are shown
in Table 2.
Median survival time after TAVI was 3.4 years (95% CI:
2.5 to 4.4), and survival rates at 1 to 5 years were 83%, 74%,
53%, 42%, and 35%, respectively (Fig. 2). Table 3 shows
univariate and multivariable predictors of mortality. In
multivariable analysis, the presence of chronic obstructive
pulmonary disease (COPD) (HR: 2.17; 95% CI: 1.18 to
3.70) and at least moderate paravalvular regurgitation
(PAR) post-TAVI (HR: 2.98; 95% CI: 1.44 to 6.17) were
Figure 2 Long-Term Survival After
Transcatheter Aortic Valve Implantation
This represents first in human transarterial and transapical experience
in nonoperative patients.
Univariate and Multivariate Predictors of MortalTable 3 Univariate and Multivariate Predict
Univariate
Variable HR (95% CI)
Female 0.83 (0.51–1.35)
Age (per year) 1.00 (0.96–1.04)
Diabetes 0.94 (0.53–1.68)
Hypertension 1.05 (0.61–1.79)
Atrial fibrillation 0.92 (0.56–1.49)
Prior CVA 1.33 (0.69–2.55)
COPD 2.32 (1.38–3.90)
GFR 60 ml/min 0.95 (0.58–1.55)
LVEF 50% 1.53 (0.87–2.67)
Transapical access 0.97 (0.55–1.69)
At least moderate PAR 2.66 (1.30–5.45)
Pulmonary hypertension 1.23 (0.67–2.27)
Prior open heart surgery 0.73 (0.44–1.23)
Patient prosthesis mismatch 0.77 (0.46–1.31)
Vascular complication 1.75 (0.93–3.29)
Bleeding complication 1.63 (0.86–3.06)Patients with unsuccessful TAVI in which no valve was implanted and patien
CVA  cerebrovascular accident; HR  hazard ratio; LVEF  left ventriculaassociated with increased risk of death. Median survival
time for patients with and without COPD was 2.3 and 3.9
years, respectively. Median survival time for patients with at
least moderate PAR and mild/trivial/no PAR was 1.7 and
3.4 years, respectively (Fig. 3).
Aortic valve area and gradients. Overall, the mean aortic
valve area increased from 0.62  0.17 cm2 before TAVI to
.67  0.41 cm2 after TAVI and was 1.40  0.25 cm2 at 5
years. The area decreased on average by 0.06 cm2/year
SE 0.01; p for trend 0.01). Mean aortic valve gradient
ecreased from 46  18 mm Hg before TAVI to 10  4.5
m Hg after TAVI and was 11.8  5.7 mm Hg at 5 years.
he gradient increased on average by 0.27 mm Hg/year
SE 0.15; p for trend  0.06) (Fig. 4). There were no
ifferences in gradients and aortic valve areas between the
ribier-Edwards and Edwards SAPIEN valves.
aravalvular regurgitation. Changes over time in valvular
nd paravalvular regurgitation are shown in Figure 5. After
AVI, 25% of patients had no PAR, 63% had mild PCR,
nd 11.4% had at least moderate PAR. PAR was at least
oderate at 1 to 5 years in 5.7%, 1.2%, 0%, 0%, and 0% of
atients, respectively.
rosthetic valve failure. Mild transvalvular regurgitation
as present in 10.3% of patients after TAVI and 9.1%,
4.3%, 11.9%, 9.5%, and 7.1% at 1 to 5 years, respectively.
p to 4 years, no patient had prosthetic valve failure. At 5
ears, 3 patients (3.4% of the total cohort) showed signs of
rosthetic valve failure. One patient had moderate transval-
ular regurgitation and moderate stenosis (aortic valve area
.2 cm2; mean gradient 26 mm Hg) 5 years after implan-
tation of a Cribier-Edwards valve. Another patient had
moderate regurgitation 5 years after implantation of a
Cribier-Edwards valve. The third patient had moderate steno-
sis (aortic valve area 1.1 cm2; mean gradient 23 mm Hg)
f Mortality
el Multivariable Model
p Value HR (95% CI) p Value
0.45
0.97
0.85
0.87
0.72
0.40
0.01 2.17 (1.28–3.70) 0.01
0.83
0.14 1.38 (0.76–2.48) 0.29
0.91
0.12 2.98 (1.44–6.17) 0.01
0.50
0.73
0.33
0.08 1.63 (0.60–4.43) 0.34
0.13 1.25 (0.46–3.42) 0.66ityors o
Modts who died within 30 days were excluded from analysis.
r ejection fraction; other abbreviations as in Tables 1 and 2.
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No patient developed severe stenosis or severe regurgitation.
One patient developed infective endocarditis 5 months
after implantation of an Edwards SAPIEN valve, under-
went surgical open valve replacement, and remained alive 5
years following TAVI.
Concomitant mitral regurgitation. At baseline, moder-
ate/severe mitral regurgitation (MR) was present in 42
patients (48%). After TAVI, moderate/severe MR had
improved to no/mild MR in 24 patients (57%). At 5
years, moderate/severe MR remained improved in 26%
and was unchanged in 16%; 58% of patients had died
(Fig. 5). No/mild MR worsened to moderate/severe in
4% of patients after TAVI and did not improve in 2% at
the 5-year follow-up.
New York Heart Association class. The rate of patients in
New York Heart Association (NYHA) class 3 or 4 was 7%,
Figure 3 Long-Term Survival Stratified by Presence/Absence
of COPD and Paravalvular Regurgitation
Survival in patients with chronic obstructive pulmonary disease (COPD) (top)
and with at least moderate paravalvular regurgitation (bottom) was signifi-
cantly reduced.8%, 6%, 2%, and 5% at 1 to 5 years, respectively (Fig. 5).Left ventricular function and diameters. Median ejection
fraction was 60% (Q1, Q3: 50%, 65%) before TAVI, 60%
(Q1, Q3: 55%, 65%) after TAVI, and 56% (Q1, Q3: 45%,
65%) at the 5-year follow-up. Left ventricular end-diastolic
diameter was 51.1  6.8 mm before TAVI, 51.5  7.2 mm
fter TAVI, and 49.2  7.0 mm at 5 years.
Stroke. During the observation period, 6 ischemic and 4
hemorrhagic major or fatal strokes occurred (Fig. 6,
Table 4). Cumulative major ischemic and hemorrhagic
stroke rates at 5 years were 9.7% and 7.3%, respectively,
and 50% were fatal.
Discussion
Our study demonstrated favorable long-term outcomes after
successful TAVI with a 5-year survival rate of 35%. Mean
aortic valve area decreased on average by 0.06 cm2/year, and
mean transvalvular gradient increased by 0.27 mm Hg/year
throughout the 5-year period. Moderate prosthetic THV
failure was observed in 3 patients at 5 years, but no patient
developed severe transvalvular regurgitation or restenosis.
Concomitant MR improved in the majority of patients and
remained improved at the 5-year follow-up. More than 90%
of patients were in NYHA class 1 or 2 during the whole
observation period. Cumulative major ischemic stroke rate
at 5 years was 9.7%.
Survival. In this patient population with a mean age of 83
years at the time of the TAVI procedure, 5-year survival was
35% and median survival after TAVI was 3.4 years exclud-
ing patients with procedural mortality (death during the first
30 days). Median survival in patients without COPD was
3.9 years but only 2.3 years in those with COPD. The other
predictor of decreased survival was paravalvular leak. Even
in these early cases representing the beginning of the
learning curve, PAR was mild or less in 90% of patients.
The remaining 10% had moderate PAR, which was asso-
ciated with reduced survival (HR: 2.98). Moderate PAR has
previously been shown to be associated with reduced sur-
vival rates with HRs/odds ratios ranging from 1.7 to 3.8
(8,14–16). Our study suggested that PAR is an independent
risk factor not only for peri-procedural but also for long-
term mortality.
Prosthetic valve failure. Up to the 4-year follow-up, no
patient demonstrated more than mild transvalvular regurgi-
tation and no patient had clinically relevant THV restenosis.
At 5 years, we observed 3 patients (3.4% of the initial group;
9.7% of patients alive) with moderate prosthetic valve
failure. One patient had moderate transvalvular regurgita-
tion, one had moderate stenosis, and one had moderate
mixed disease. None of the patients had severe regurgitation
or stenosis, and no patient required reoperation or reinter-
vention due to structural valve failure. In the PARTNER
(Placement of Aortic Transcatheter Valves) trial, moderate
or severe transvalvular aortic regurgitation was present in
0.9% (PARTNER 1A) and 4% (PARTNER 1B) of pa-
417JACC Vol. 61, No. 4, 2013 Toggweiler et al.
January 29, 2013:413–9 5-Year Outcome After TAVIFigure 4 Mean Aortic Valve Gradients and Aortic Valve Area
Mean gradients and aortic valve area remained stable with only marginal increase in gradient and mild decrease in valve area over time.
There were no differences in gradients and aortic valve areas between the Cribier-Edwards valve and the Edwards SAPIEN valve.Figure 5 Paravalvular and Valvular Regurgitation, NYHA Class, and Mitral Regurgitation
Paravalvular aortic regurgitation, valvular aortic regurgitation, mitral regurgitation, and New York Heart Association (NYHA) class are shown over the 5-year observation period.
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5-Year Outcome After TAVI January 29, 2013:413–9tients after TAVI and in no patients after surgical aortic
valve replacement (SAVR) at the 1-year follow-up. Mild
transvalvular regurgitation was frequently present in 62%
and 63% of patients after TAVI and 45% of patients after
Figure 6 Ischemic and Hemorrhagic Stroke Rates
The annual risk of ischemic strokes was about 2% and persisted up to
5 years. At the same time, the major hemorrhagic stroke rate at 1 to 5 years
was 2.8%, 4.4%, 4.4%, 7.3%, and 7.3%, respectively, and 50% of these events
were fatal.
Ischemic and Hemorrhagic StrokesTable 4 Ischemic and Hemorrhagic Strokes
Stroke Type Days Post-TAVI Risk Fac
Ischemic 2 Atrial fibri
Ischemic 54 None
Ischemic 119 Atrial fibri
Ischemic 637 None
Ischemic 902 Carotid ste
Ischemic 1,674 Atrial fibri
Hemorrhagic 203 Atrial fibri
Hemorrhagic 211 Atrial fibri
Hemorrhagic 608 Atrial fibri
Hemorrhagic 1,405 NoneAbbreviation as in Table 2.SAVR (4,5). Reported rates of structural valve deterioration
n surgically implanted aortic valve bioprostheses requiring
eoperation range widely from 6% to 47% by 12 to 20
ears after surgical implantation (17–20). Larger studies
re needed to determine the rate of structural deteriora-
ion of THVs.
itral regurgitation. Previously, our group reported that
oncomitant moderate or severe MR was associated with
ncreased early but not late mortality in patients undergoing
AVI (21). We also reported that moderate or severe MR
mproved in 61% of patients after TAVI and remained
mproved in 55% at the 1-year follow-up. In the present
ohort, concomitant moderate or severe MR was present in
8% of patients before TAVI and subsequently improved in
5% after TAVI. At 5 years, MR was improved in 26% of
atients and remained unchanged in 16%; 58% of patients
ad died.
troke. Neurological events have appeared as one of the most
ontroversial complications in TAVI. In the PARTNER trial,
he rate of strokes was higher after TAVI than after SAVR,
lthough the rate of major strokes did not differ (4,5,22).
umulative major ischemic stroke rate at 5 years was 9.7%,
ndicating an annual risk of ischemic strokes of approxi-
ately 2% that appeared to persist up to 5 years. At the
ame time, the cumulative major hemorrhagic stroke rate at
years was 7.3%.
tudy limitations. Our data represent the experience of a
ingle center rather than outcomes of a clinical trial, and
hey are self-reported with no external independent data
djudication. The number of patients was small, and mul-
ivariable predictors of mortality should be confirmed in a
arger sample.
onclusions
ur study demonstrated favorable outcomes 5 years after
uccessful TAVI with excellent hemodynamics and signs of
oderate prosthetic valve failure observed in only 3.4% of
atients. No patient developed severe valvular regurgitation
r stenosis.
Antiplatelet Regimen Outcome
Aspirin, clopidogrel Patient survived
Aspirin, clopidogrel Patient died
Warfarin Patient died
Aspirin Patient survived
Aspirin Patient died
Aspirin, clopidogrel Patient survived
Warfarin, aspirin Patient died
Warfarin Patient died
Warfarin Patient survived
Aspirin, clopidogrel Patient survivedtors
llation
llation
nosis
llation
llation
llation
llation
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